Application of CRISPR genetic screens to investigate neurological diseases
Author(s)
So, Raphaella W L; Chung, Sai W; Lau, Heather H C; Watts, Jeremy J; Gaudette, Erin; Al-Azzawi, Zaid A M; Bishay, Jossana; Lin, Lilian T; Joung, Julia; Wang, Xinzhu; Schmitt-Ulms, Gerold; ... Show more Show less
Download13024_2019_Article_343.pdf (1.361Mb)
Publisher with Creative Commons License
Publisher with Creative Commons License
Creative Commons Attribution
Terms of use
Metadata
Show full item recordAbstract
The adoption of CRISPR-Cas9 technology for functional genetic screens has been a transformative advance. Due to its modular nature, this technology can be customized to address a myriad of questions. To date, pooled, genome-scale studies have uncovered genes responsible for survival, proliferation, drug resistance, viral susceptibility, and many other functions. The technology has even been applied to the functional interrogation of the non-coding genome. However, applications of this technology to neurological diseases remain scarce. This shortfall motivated the assembly of a review that will hopefully help researchers moving in this direction find their footing. The emphasis here will be on design considerations and concepts underlying this methodology. We will highlight groundbreaking studies in the CRISPR-Cas9 functional genetics field and discuss strengths and limitations of this technology for neurological disease applications. Finally, we will provide practical guidance on navigating the many choices that need to be made when implementing a CRISPR-Cas9 functional genetic screen for the study of neurological diseases.
Date issued
2019-11-14Department
Massachusetts Institute of Technology. Department of Biological Engineering; Massachusetts Institute of Technology. Department of Brain and Cognitive Sciences; McGovern Institute for Brain Research at MIT; Broad Institute of MIT and HarvardJournal
Molecular Neurodegeneration
Publisher
BioMed Central
Citation
So, Raphaella W.L., et al. "Application of CRISPR genetic screens to investigate neurological diseases." Molecular Neurodegeneration 14 (2019): 41. https://doi.org/10.1186/s13024-019-0343-3
Version: Final published version
ISSN
1750-1326